Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.40 |
| ▸ | F7 | P08709 | 1/20 | 0.40 |
| ▸ | F3 | P13726 | 1/20 | 0.40 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.40 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.40 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.40 |
| ▸ | JUN | P05412 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3407188 | 0.81 | NNMT (0.56) | NNMTSMN1; SMN2SIRT6LMNAL3MBTL1 | |
| SCHEMBL1745778 | 0.77 | NNMT (0.52) | NNMTSMN1; SMN2SIRT6LMNAL3MBTL1 | |
| SCHEMBL63857 | 0.77 | NAPRT (0.58) | KDM4ENAPRTJUNNFKB1NFKB2 | |
| SCHEMBL6987829 | 0.77 | NAPRT (0.46) | SMN1; SMN2SIRT6L3MBTL1NAPRTJUN | |
| SCHEMBL3141529 | 0.77 | NNMT (0.58) | NNMTSMN1; SMN2SIRT6LMNAL3MBTL1 | |
| SCHEMBL669121 | 0.77 | NNMT (0.52) | NNMTSMN1; SMN2SIRT6LMNAL3MBTL1 | |
| SCHEMBL23193160 | 0.75 | NNMT (0.50) | NNMTSMN1; SMN2SIRT6LMNAL3MBTL1 | |
| SCHEMBL600134 | 0.75 | NAPRT (0.40) | SMN1; SMN2LMNAL3MBTL1KDM4ENAPRT | |
| SCHEMBL388168 | 0.75 | NAPRT (0.67) | NNMTSMN1; SMN2SIRT6L3MBTL1KDM4E | |
| SCHEMBL29524193 | 0.75 | NAPRT (0.67) | NNMTSMN1; SMN2SIRT6L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110372604-A | A kind of synthetic method of the chloro- 5- pyrimidine carboxamide of 2,4- bis- | 南京普锐达医药科技有限公司 | 2019-10-25 | — | — | CN | claimed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667467-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-20250326754-A1 | DNA-PK Inhibitor Compounds and Uses Thereof | ADMARE THERAPEUTICS SOC (CA) | 2025-10-23 | — | — | US | disclosed |
| EP-4522620-A1 | DNA-PK INHIBITOR COMPOUNDS AND USES THEREOF | Admare Therapeutics Society (CA) | 2025-03-19 | — | — | EP | disclosed |
| US-20240246960-A1 | 7-Morpholino-L,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2024-07-25 | — | — | US | disclosed |
| WO-2024054955-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054953-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054954-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| CN-117658992-A | Benzimidazole compound, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2024-03-08 | — | — | CN | disclosed |
| CN-104418866-B | Dgat1 inhibitor and its preparation method and application | 青岛黄海制药有限责任公司 | 2018-10-16 | — | — | CN | disclosed |
| WO-2018092089-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018092089-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-24 | — | — | WO | disclosed |
| EP-3204363-A1 | SUBSTITUTED PYRIMIDINES AS INHIBITORS OF HIF PROLYL HYDROXYLASE | Merck Sharp & Dohme Corp. (US) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016057762-A1 | SUBSTITUTED PYRIMIDINES AS INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP (US) | 2016-04-14 | — | — | WO | disclosed |
| CN-104418866-A | DGAT1 inhibitor, and preparation method and application thereof | NANJING MINGDE NEW DRUG RES AND DEV CO LTD | 2015-03-18 | — | — | CN | disclosed |
| CN-102348707-A | Pyrimidinecarboxamide derivatives as inhibitors of SYK kinase | GLAXO GROUP LTD | 2012-02-08 | — | — | CN | disclosed |
| US-20110152295-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2011-06-23 | — | — | US | disclosed |
| EP-2334666-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Canada Inc. (CA) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010025553-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246960-A1 | 7-Morpholino-L,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | DCK, ERCC2, POLK | NNMT 760/4885SMN1; SMN2 2120/4885SIRT6 1928/4885 |
| US-20250326754-A1 | DNA-PK Inhibitor Compounds and Uses Thereof | DCK, CHEK1, CHEK2 | NNMT 1375/4885SMN1; SMN2 3102/4885SIRT6 1308/4885 |
| US-20110152295-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, SREBF1 | NNMT 810/4885SMN1; SMN2 2669/4885SIRT6 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.